U.S. FDA approves Vanda's circadian rhythm drug Hetlioz
(Reuters) - Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its experimental drug to regulate the internal body clocks of blind patients and help normalize sleep patterns.
The drug, Hetlioz, is designed to treat Non-24-Hour Sleep-Wake Disorder, or Non-24, a condition that is common among the totally blind, which can cause disrupted nighttime sleep patterns and excessive daytime sleepiness.
Vanda's shares rose 8.1 percent to $14.15 in afternoon trading after initially rising as high as $15.59 on the news.
- Still no sign of Malaysian jet lost in 'unprecedented mystery' |
- The search for missing Malaysian jet
- Mexico kills drug kingpin reported dead years ago: official
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source